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Severe fever with thrombocytopenia syndrome (SFTS) is an emerging viral disease that is endemic in
China, Korea and Japan. No effective vaccine or speciﬁc treatment for SFTS is currently available. Here, we
used a mouse model to examine the effects of ribavirin, site-1 protease inhibitor PF-429242, steroids,
and combination of minocycline and ciproﬂoxacin (MC) on SFTS infection. The antiserum from a patient
who recovered from SFTS was also examined for its effect on mice. Administration of antiserum
completely protected mice against lethal infection with SFTSV. It could also protect mice from showing
clinical signs of the disease due to non-lethal infection. MC-treatment resulted in prolonged survival
times during lethal infection. Although other agents had no signiﬁcant protective effects, they did not
provide detrimental effects that could lead to progression of the disease in mice. Our results suggest that
antiserum treatment may be clinically useful for post-exposure prophylaxis against SFTSV infection.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Severe fever with thrombocytopenia syndrome (SFTS) is an
emerging disease that was ﬁrst reported in rural areas of central
China in 2009 (Yu et al., 2011). SFTS is currently identiﬁed in Korea
and Japan (Kim et al., 2013; Takahashi et al., 2014). To date, more
than 2500 cases have been conﬁrmed in China (2047 cases during
2011–2012) with mortality ranging from 6.3% to 30% (Liu et al.,
2014a, 2014b). In Japan speciﬁcally the western part, a total of 113
cases (37 deaths) had been identiﬁed until the year 2014
(Yamaguchi Prefectural Surveillance Center of Infectious Disease,
2015). The earliest case among all the reported SFTS cases world-
wide was from a patient in Nagasaki who was infected in 2005
(Takahashi et al., 2014).
The causative agent, SFTS virus (SFTSV), belongs to the genus
Phlebovirus in the family Buniyaviridae (Yu et al., 2011). The SFTSV
is transmitted to humans through the bite of an infected tick
(Zhang et al., 2012). Human-to-human-transmission occurs
through contact to the blood of an infected person (Chen et al.,
2013; Liu et al., 2012; Tang et al., 2013; Wang et al., 2014) and this
may be through mucous membranes or skin wounds of the
healthy person.
Clinical manifestations of SFTS are fever, headache, fatigue,
myalgia, gastrointestinal symptom such as vomiting and diar-
rhea, thrombocytopenia and leukopenia, with fatality rates ran-
ging from a few percent up to 30% (Liu et al., 2014a, 2014b;
Takahashi et al., 2014; Yu et al., 2011). Although details of the
mechanism of severe disease are not fully understood, it was
reported that viral copy numbers in the blood or serum in the
fatal cases were signiﬁcantly higher than in those with survival
outcomes (Gai et al., 2012; Yoshikawa et al., 2014). Thus, sup-
pression of viral replication in patients is an important option for
therapeutic treatment of the fatal form of the disease. In China,
ribavirin has been prescribed to SFTS patients as an attempt to
treat them (Liu et al., 2013; Oh et al., 2014). In Japan, clinicians
have tried to treat severe SFTS patients with steroid such as
methylprednisolone for treatment of hemophagocytic syndrome
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(IASR, 2013). However, the effects in vivo are unclear, and no
effective vaccine or speciﬁc treatment for SFTS is currently
available.
Injection of antiserum or blood transfusion to patients has been
attempted to treat some viral diseases namely, Ebola Hemorrhagic
Fever, SARS coronavirus, rabies and tick-borne encephalitis (Broker
and Kollaritsch, 2008; Khawplod et al., 1996; Mair-Jenkins et al.,
2015; Mupapa et al., 1999). Antiviral agents such as nucleotide
analogs or protease inhibitors may also be candidates for ther-
apeutic treatment of SFTS. Ribavirin, a guanosine analog, has been
shown to be effective for treatment of some viral diseases
(Keshtkar-Jahromi et al., 2011; Lange et al., 2014; McCormick
et al., 1986; Sidwell and Barnard, 2006). PF-429242, the cellular
protease subtilisin kexin isozyme-1 (SKI-1)/site-1 protease (S1P)
inhibitor, has been shown to have antiviral activity against some
RNA viruses (Olmstead et al., 2012; Pasquato et al., 2012; Urata
et al., 2011). In vitro experiments suggest that PF-429242 has a
suppressive effect on SFTSV propagation in cultured cells (unpub-
lished data ) and this raised the possibility of the antiviral effects
of PF-429242.
In Japan, endemic areas of SFTS overlap with the region of the
Japanese spotted fever, the causative agent of which is Rickettsia
japonica. This agent is also transmitted by ticks (Mahara, 1997). In
these areas, febrile patients with tick bites are suspected to have
spotted fever, and they are generally treated with antibiotics such
as minocycline (MINO) and ciproﬂoxacin (CPFX) in the early
phases of the disease. However, it is not known whether these
antibiotics treat or exacerbate SFTS infection.
To elucidate the pathogenesis of SFTSV infection in vivo, labora-
tory mouse model such as C57/BL6, BALB/c and Kunming strains
have been used (Chen et al., 2012; Jin et al., 2012). However, adult
mice of these strains do not exhibit apparent clinical signs and no
mice have fatal outcome, indicating that these immunocompetent
adult mice are not susceptible to SFTSV. On the other hand, alpha/
beta interferon receptor knockout (IFNAR/) mice are highly
susceptible to SFTSV infection and adult mice have been reported
to die following subcutaneous inoculation of 106 focus-forming units
(ffu) of SFTSV (Liu et al., 2014c). Thus, IFNAR / mice are regarded as
useful animals for SFTSV infection model in vivo.
In this study, we investigated the effects of ribavirin, PF-429242,
steroids and human antiserum on SFTSV infection using an IFNAR /
mouse model. Furthermore, we also examined the effects of MINO
and CPFX on the same mouse model following SFTSV infection.
Results
Lethal and non-lethal models of SFTSV infection in IFNAR KO mice
To examine the pathogenicity of the YG-1 strain of SFTSV and to
observe clinical signs in mice, 129 strain background IFNAR KO
(A129) mice were subcutaneously inoculated with high (106 ffu)
and low (102 ffu) doses of SFTSV. High dose-infected mice devel-
oped acute clinical signs including piloerection, slowness in move-
ment, anorexia and severe weight loss after 2 days post-infection
(pi). All of them died by 7 days pi (Fig. 1A and B). On the other
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Fig. 1. Mortality, weight change and viral loads of A129 mice following subcutaneous infection with high (106 ffu) and low (102 ffu) doses of SFTSV. (A) Survival curves.
(B) Weight changes. The weight ratio was calculated by comparing the weight of each mouse with its weight at day 0. Mice were observed for 14 days (n¼5). None of the
mice died after 7 days, and the data were shown for 10 days. (C) Viral copy numbers in the spleen at 1 and 3 days (n¼3). p: Student's test.
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hand, low dose-infected mice exhibited weight reduction during
the 3–6 days pi and recovered after 7 days pi (Fig. 1A and B). Viral
loads in the spleens of high dose-infected mice were signiﬁcantly
higher than those of the low dose-infected mice at 1 and 3 days pi
(Fig. 1C). These observations indicated that high and low dose
infections in A129 mice represent lethal and non-lethal models of
SFTSV infection, respectively.
Effect of treatment with ribavirin, PF-429242, steroids and antiserum
on SFTSV infection in vivo
We next examined the therapeutic effects of ribavirin, PF-
429242, steroids and antiserum in A129 mice infected with high
and low doses of SFTSV (Figs. 2 and 3). Antiserum was collected
from a recovered SFTS human case, and this serum had a 1:2000
neutralizing antibody titer measured by 50% focus reduction
neutralization.
Following lethal infection with SFTSV, all groups of mice had
acute weight reduction similar to saline (mock)-treated mice
(Fig. 2B). All of the PF-429242- and steroid-treated mice died,
but one of ﬁve mice survived with ribavirin treatment (Fig. 2B and
C). All mice survived after treatment with antiserum, although
their weight reductions were similar to those of mock-treated
mice during the 2–5 days pi (Fig. 2B and C).
Following non-lethal infection with SFTSV, mock-, ribavirin-,
PF-429242- and steroid-treated mice showed weight reduction
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Fig. 2. Mortality and weight changes of drugs- and antiserum-treated A129 mice infected with 106 ffu of SFTSV. (A) Schedule of the administration of saline, ribavirin, PF-
429242, steroid and antiserum following SFTSV infection. Black arrow indicates the time of SFTSV infection. Gray arrows indicate the time of drugs and antiserum
administration. h¼hour. (B) Weight ratio of individual mice in each agent-treated group. The weight ratio is indicated compared with weights at day 0. (C) Survival curves in
saline-, ribavirin-, PF-429242-, steroid- and antiserum-treated groups (n¼5).
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(Fig. 3B). Although all of the mock-, PF-429242- and steroid-
treated mice had more than 10% weight reduction, three out of
the ﬁve ribavirin-treated mice showed only slight (less than 10%)
decreases in weight (Fig. 3B). Antiserum-treated mice, however,
did not exhibit signiﬁcant weight reduction or any clinical
signs (Fig. 3B).
These results suggest that antiserum from SFTS patients has
potential therapeutic effects against both lethal and non-lethal
SFTSV infection in vivo. Although ribavirin had no statistically
signiﬁcant effect, it showed a slight protective effect in both lethal
and non-lethal infections. PF-429242 and steroid treatments did
not show apparent therapeutic beneﬁt for SFTS infection, however,
they did not seem to add detrimental effects during the progres-
sion of the disease in mice.
Suppressive effect of antiserum on viral replication in mice following
lethal infection
Antiserum exhibited signiﬁcant protection against fatal infec-
tion with SFTSV; thus, we compared viral loads in A129 mice
infected with lethal doses of SFTSV during treatment with anti-
serum or mock saline.
During 1–3 days pi, copy numbers of viral RNA in the lung,
spleen, liver, kidney, brain and spinal cord were not signiﬁcantly
different between mock- and antiserum-treated groups (Fig. 4).
However, at 4 days pi, the levels in the spleen, kidney, and brain of
antiserum-treated mice were signiﬁcantly lower than those of the
mock-treated mice (Fig. 4). Although the differences in other
tissues were not signiﬁcant, levels in the lung and liver tended
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to be lower in the antiserum-treated mice than in the mock-
treated mice at 4 days pi (Fig. 4).
Thus, it seems that the mice treated with antiserum had
suppressed levels of viral replication. However, more evidences
are required to show if the antiserum has really an effect on virus
replication and help rescue mice from lethal infection. Other
mechanisms may contribute to the rescue of mice from lethal
infection with SFTSV.
Timing of efﬁcient treatment with antiserum
We next examined the timing of effective treatment with
antiserum on SFTSV infection in mice (Fig. 5A). When antiserum
treatment was started at 24 h and 48 h, lethal dose-infected mice
showed 20% and 0% survival rates, respectively (Fig. 5B). Weight
reductions in these groups were similar to those of the control
group (Fig. 5B). Survival rates and weight changes of non-lethal-
infected mice were not signiﬁcantly different among the three
groups (24 h, 48 h and control) (Fig. 5C). These observations
suggest that early treatment with antiserum is important for
having a signiﬁcant effect on SFTSV infection.
Effects of MINO and CPFX on SFTSV infection
We next investigated the effects of MINO and CPFX on SFTSV
infection in mice following a lethal dose infection (Fig. 6A). Although
all mice died, survival times of minocycline and ciproﬂoxacin (MC)-
treated mice were slightly longer than those of mock-treated mice
(Fig. 6B). Their weight changes were not signiﬁcantly different
(Fig. 6B). Viral loads in the spleen, liver and brain cortex at 4 days pi
were not signiﬁcantly different betweenMC- andmock-treated groups
(Fig. 6C). Therefore, MC-treatment may have some inﬂuences on
lessening the severity of the SFTSV infection by a route other than
simple suppression of viral replication in mice.
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Discussion
In this study, we showed in an in vivo mouse model, that post-
exposure prophylaxis for SFTS with human antiserum completely
protected mice against lethal infection with SFTSV. This treatment
also protected mice from clinical signs after infection with non-
lethal doses of SFTSV. These suggest that antiserum treatment is
clinically useful for post-exposure prophylaxis against SFTSV
infection.
Our results showed that early treatment with antiserum was
required for efﬁcient recovery from disease as shown in the mouse
model. However, in natural infections of SFTSV after tick bites, it is
difﬁcult to do the anti-serum treatment soon after infection. On
the other hand, SFTSV can infect through direct contact with
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infected blood or bloody secretions (Chen et al., 2013; Tang et al.,
2013). Thus, antiserum treatment is likely to be more useful for
individuals such as hospital health-care workers and relatives of
patients who may have a hospital-acquired infection.
The antiserum used in this study showed high neutralizing
antibody titers (1:2000), and treatment with this serum resulted
in suppressive effects against SFTSV replication in vivo. Here,
500 μl of inoculum (1:10 dilution of serum) per mouse was
injected four times every 24 h. However, it would be difﬁcult to
prepare and inject the same scale of inoculum volume in human
cases. Thus, further improvement in the production of efﬁcient
and abundant amounts of anti-viral antibodies with high neutra-
lizing activity is needed to provide a practical strategy for treat-
ment of SFTS. Alternatively use of pooled antisera could also
provide a practical clinical source.
It has been reported that ribavirin is effective against some RNA
virus infections such as hepatitis C virus (Lange et al., 2014), Lassa
fever virus (McCormick et al., 1986), Crimean-Congo hemorrhagic
fever virus (Keshtkar-Jahromi et al., 2011) and respiratory syncytial
virus (Sidwell and Barnard, 2006). In practice, a combination antiviral
therapy of ribavirin, interferon and other agents such as sofosbuvir
has been used as a standard treatment for hepatitis C (Dhingra et al.,
2014). The inhibitory effects of ribavirin against SFTSV replication
were recently shown in an in vitro assay (Shimojima et al., 2014). In
this study, slight protective effects were observed after ribavirin
treatment, although the difference was not statistically signiﬁcant.
Therefore, a combination of ribavirin with other antiviral agents may
possibly be an effective treatment for this disease.
MC treatment resulted in prolonged survival times in mice
compared with non-treated mice following lethal infection with
SFTSV. However, viral loads in the tissues were not signiﬁcantly
different between MC- and mock-treated groups. Thus, an unknown
mechanism of MINO or CPFX may contribute to the prolonged
survival effect. It is noteworthy that MC treatment is unlikely to
exacerbate the disease course due to SFTSV infection. Thus, MC
treatment should be considered in suspected cases of spotted fever
caused by Rickettsia Japonica in the endemic area in Japan, even
though diagnosis of spotted fever or SFTS is not deﬁnitive.
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For animal models of SFTSV infection, immunocompetent mice
and hamsters were studied, but these adult animals did not show
apparent disease (Chen et al., 2012; Jin et al., 2012; Liu et al., 2014c).
Liu et al. showed that IFNAR / mice were highly susceptible to
SFTSV infection (Liu et al., 2014c). In this study, we used IFNAR/
mice of the same background strain (129/Sv) reported previously
(Liu et al., 2014c), but we used different virus strain (Japanese
isolate YG-1 strain) for virus challenges. The previous study showed
only fatal infection with 106 ffu of SFTSV. Here, we also showed that
106 ffu of SFTSV (YG-1 strain) caused lethal infection. Furthermore,
we showed that inoculations with 102 ffu of SFTSV caused non-
lethal infection. Non-lethal infection induced clinical signs including
weight reduction, but the mice survived. In human cases, it has
been suggested that the patient's viral load is related to disease
severity (Gai et al., 2012; Yoshikawa et al., 2014). Thus, a comparison
of different infective doses may provide a promising approach to
elucidate the mechanism of SFTS severity. Furthermore, dose-
dependent mouse models of SFTSV infection are needed for
evaluation of future antiviral drugs for post-exposure prophylaxis
against SFTSV infection.
Conclusion
In this study, we showed that post-exposure prophylaxis with
human antiserum from an SFTS patient had signiﬁcant therapeutic
effects on SFTSV infection in an in vivo mouse model. Our results
strongly suggest that antiserum treatment may be clinically useful
for post-exposure prophylaxis against SFTSV infection.
Materials and methods
Virus and cells
The YG-1 strain of SFTSV was kindly provided by Ken Maeda,
Yamaguchi University (Takahashi et al., 2014). Stock virus of SFTSV
was prepared from cell culture medium of Vero E6 cells. Vero E6
cells were maintained in Eagle's Minimal Essential Medium
(EMEM; Nissui Pharmaceutical Co.) containing 10% fetal bovine
serum (FBS). All experiments using live SFTSV were performed in a
biosafety level 3 laboratory at Nagasaki University according to
standard BSL3 guidelines.
Antiserum from a recovered SFTS case-patient
Serum was collected from the patient who contracted the
disease in 2005. Collection was done after eight years from the
recovery of the patient. Control serum was collected from a
healthy volunteer who had not been infected with SFTSV. The
experiment using human serum was performed with the approval
of the ethics committee of the Institute of Tropical Medicine,
Nagasaki University (Approval number: 140829129).
Focus forming assay
The SFTSV titer was determined in a focus forming assay.
Conﬂuent Vero E6 cells were inoculated with serially diluted
culture supernatants of SFTSV stock and incubated in 2% FCS
EMEM containing 1% methyl cellulose 4000 (Wako Pure Chemical
Industries, Ltd.) for 5 days. Viral foci were detected using SFTSV
antiserum, peroxidase-conjugated anti-human IgG (American
Qualex) and DAB substrate (Wako Pure Chemical Industries,
Ltd.). Viral titers were expressed as ffu/ml.
Neutralization test
The neutralizing antibody titers of the antiserum were deter-
mined by focus-reduction assay. Serially diluted sera were mixed
with SFTSV and incubated at 37 1C for 1 h. Vero E6 cells were
inoculated with the mixtures and incubated for 5 days. Focus
staining was performed as described above. The neutralizing titer
was determined as the reciprocal of the highest serum dilution
that reduced the viral foci counts by 50%.
Mice
A129 mice were purchased from B & K Universal limited. These
mice were mated in the facility at Nagasaki University. Adult (older
than eight-week-old) mice were subcutaneously inoculated with
102 and 106 ffu of SFTSV diluted in EMEM containing 2% FBS. Mice
were weighed daily and observed for clinical signs.The experi-
mental protocols were approved by the Animal Care and Use
Committee of the Nagasaki University (approval number:
1401201115).
Treatment with drugs and antiserum in mice
Ribavirin (Wako Pure Chemical Industries, Ltd.), PF-429242
(AdooQ BioScience) and steroids (Methylprednisolone sodium
succinate, Sawai Pharmaceutical Co., Ltd.) were diluted in saline,
and 500 μl of each diluent was intraperitoneally administered to
A129 mice at 2 mg, 1 mg and 0.4 mg per mouse, respectively, at 1,
24, 48 and 72 h following infection with SFTSV (Figs. 2A and 3A).
MINO (Minomycins, Pﬁzer Japan Inc.) and CPFX (Nichi-Iko Phar-
maceutical Co., Ltd.) were diluted in saline, and the mixture
(500 μl) was intraperitoneally injected as 1 mg of each antibiotic
per mouse at 1, 24, 48 and 72 h after inoculation with SFTSV
(Fig. 6A). Sera were diluted tenfold in saline, and 500 μl of diluent
was intraperitoneally injected at 1, 24, 48, 72 and 92 h after
inoculation with SFTSV (Figs. 2A, 3A and 4A). Saline or a diluent
of the control serum at the same volume of the drugs or antiserum
was used for mock treatment.
Virus titration in mouse tissues
One to four days pi, three to ﬁve mice were sacriﬁced, and lung,
spleen, liver, kidney, brain and spinal cord were collected following
perfusion with cold phosphate-buffered saline. Brains were divided
into two fractions: cortex and non-cortex. The tissues were imme-
diately submerged in RNAlater (Ambion) and were stored at 80 1C
until use. Total RNA was extracted using an RNeasy Lipid Tissue Mini
Kit (Qiagen). Viral copy numbers were examined by real-time RT-
PCR. SFTSV-speciﬁc primers and a probe were designed based on the
RdRp region of the consensus sequences of the L segment. The
forward primer was SFTS_QPCR_965F: 50-GCRAGGAGCAACAAR-
CAAACATC-30, the reverse primer was SFTS_QPCR_1069R: 50-
GCCTGAGTCGGTCTTGATGTC-30 and the PrimeTimes qPCR probe
was FAM/50-CTCCCRCCC-30/ZEN/50-TGGCTACCAAAGC-30/IBFQ (Inte-
grated DNA Technologies). Real-time RT-PCR reactions were per-
formed using a One Step PrimeScript RT-PCR Kit (Takara Bio Inc) and
a 7500 Real-time RT-PCR System (Applied Biosystems). The copy
numbers were calculated as a ratio of the copy numbers of the
standard control.
Statistical analyses
A Gehan–Breslow–Wilcoxon Test was performed to assess the
survival curves of SFTSV-infected groups of mice. A Mann Whitney
test was used to assess the signiﬁcant differences in viral RNA
levels.
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